Review

Update on Raltegravir and the Development of New Integrase Strand Transfer Inhibitors

Authors: Caitlin Lee Shamroe, PharmD, Paul Brandon Bookstaver, PharmD, BCPS (AQ-ID), Kristina E.E. Rokas, PharmD, Sharon B. Weissman, MD

Abstract

Raltegravir (RAL) is the first antiretroviral in the integrase strand transfer inhibitors (INSTI) class. The use of RAL has expanded since its approval in October 2007 for multidrug-resistant human immunodeficiency virus type 1 infection in adults. RAL is now a guideline-preferred treatment option for antiretroviral-naïve patients, indicated for treatment in adolescents, and is being studied as an integral part of nucleoside sparing regimens. The development of resistance and the need for a once-daily dosing option has led to the development of new INSTIs, including elvitegravir and dolutegravir. Elvitegravir is being studied in a promising once-daily single-tablet regimen with tenofovir, emtricitabine, and the investigational pharmacoenhancer cobicistat. The development of cobicistat and the new once-daily INSTIs may revolutionize the treatment of human immunodeficiency virus type 1 infection. This article reviews the current literature on raltegravir and new developments in the INSTI class.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Isentress (raltegravir) [package insert]. Whitehouse Station, NJ, Merck & Co, 2011.
 
2. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 254–258.
 
3. Marinello J, Marchand C, Mott BT, et al. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008; 47: 9345–9354.
 
4. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83: 293–299.
 
5. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48: 489–492.
 
6. Sandkovsky US, Swindells S, Robbins BL, et al. Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2011; Chicago.
 
7. Vispo E, Barreiro P, Maida I, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010; 11: 197–204.
 
8. Eron J, Rockstroh J, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907–915.
 
9. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacyof the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261–1269.
 
10. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35: 1657–1563.
 
11. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2852–2856.
 
12. Garvey L, Latch N, Erlwein OW, et al. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antivir Ther 2010; 15: 213–218.
 
13. Goldwirt L, Braun J, de Castro N, et al. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother 2011; 55: 3613–3615.
 
14. Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic evaluation of darunavir/ritonavir and raltegravir in healthy subjects. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America meeting; October 25–28, 2008; Washington, DC.
 
15. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321–333.
 
16. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52: 4228–4232.
 
17. Do VT, Higginson RT, Fulco PP. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine. Am J Health Syst Pharm 2011; 68: 2049–2054.
 
18. Hanley WD, Wenning LA, Moreau A, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53: 2752–2755.
 
19. Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol 2011; 51: 943–950.
 
20. Neely M, Decosterd L, Fayet A, et al. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 4619–4625.
 
21. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis 2008; 47: 137–140.
 
22. Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther 2010; 15: 1107–1114.
 
23. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008; 52: 3253–3258.
 
24. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008; 52: 4338–4343.
 
25. Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010; 69: 51–57.
 
26. Rhame F, Long M, Acosta A. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults. Paper presented at: International AIDS Conference; August 3–8, 2008; Mexico City.
 
27. Luber A, Slowinski PD, Acosta E, et al. Steady-state pharmacokinetics of fosamprenavir and raltegravir alone and combined with unboosted and ritonavir-boosted fosamprenavir. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2009; San Francisco.
 
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed October 29, 2011.
 
29. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010; 54: 4999–5003.
 
30. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetic evaluation of drug interactions with ritonavir boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents. Paper presented at:I International Workshop on Clinical Pharmacology of HIV Therapy; April 16–18, 2007; Budapest.
 
31. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464: 232–236.
 
32. Moss D, Murphy M, Siccardi M, et al. Influence of pH on transcellular permeability of raltegravir: unraveling the interaction with antacids and food. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 27–March 2, 2011; Boston.
 
33. Roberts JL, Kiser JJ, Hindman JT, et al. Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium. Pharmacotherapy 2011; 31: 298e–302e.
 
34. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50: 605–612.
 
35. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339–354.
 
36. Boulet T, Pavie J, Charreau I, et al. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin Trials 2010; 11: 283–293.
 
37. Towner W, Klein D, Kerrigan HL, et al. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J AIDS 2009; 51: 367–373.
 
38. Gallien S, Braun J, Delaugerre C, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011; 66: 2099–2106.
 
39. Santos JR, Llibre JM, Ferrer E, et al. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clin Trials 2009; 10: 432–438.
 
40. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396–407.
 
41. Martinez E, Larrousse M, Lilbre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697–1707.
 
42. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7.
 
43. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203: 960–968.
 
44. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J AIDS 2010; 55: 39–48.
 
45. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicenter, double-blind randomized controlled trial. Lancet 2009; 374: 796–806.
 
46. Rockstroh JK, Lennox J, DeJesus E, et al. Raltegravir (RAL) demonstrates durable virologic suppression and superior immunologic response with a favorable metabolic profile through 3 years of treatment (tx): 156 week (wk) results from STARTMRK (abstract 542). Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 27– March 2, 2011; Boston.
 
47. Young B, Vanig T, DeJesus E, et al. Long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and raltegravir (RAL) in antiretroviral naïve HIV-1 infected subjects (abstract CDB276). Paper presented at:International AIDS Society meeting; July 17–20, 2011; Rome.
 
48. Gotuzzo E, Nguyen B, Markowitz M, et al. Sustained efficacy and tolerability of raltegravir after 240 weeks of combination ART in treatment-naïve HIV-1 infected patients; final analysis of protocol 004. Paper presented at: International AIDS Society meeting; July 17–20, 2011; Rome.
 
49. Kozal MJ, Lupo S, DeJesus E, et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID (ATV+RAL) in treatment-naïve HIV-infected subjects (abstract THLBB204). Paper presented at: International AIDS Conference; July 18–23, 2010; Vienna.
 
50. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262). AIDS 2011; 25: 2113–2122.
 
51. Bedimo R, Drechsler H, Turner D, et al. RADAR study: raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naïve patients. Paper presented at: International AIDS Society meeting; July 17–20, 2011; Rome.
 
52. Bowman V, Rieg G, Jain S, et al. 48 week results of a pilot randomized study of a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen of raltegravir (RAL) + lopinavir/ritonavir (LPV/r) versus efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) in antiretro (abstract CDB336). Paper presented at: International AIDS Society meeting; July 17–20, 2011; Rome.
 
53. Gathe J, Reynes J, Pulido F, et al. Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) in antiretroviral-naïve subjects: 96-week efficacy and safety results of the PROGRESS study. Paper presented at: Infectious Disease Society of America meeting; October 20–23, 2011; Boston.
 
54. Mathias AA, West S, Hui J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 85: 64–70.
 
55. Mathias A, West S, Enejosa J, et al. A pharmacokinetic interaction between lopinavir/r and elvitegravir. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2007; Chicago.
 
56. Mathias A, Ramanathan S, Hinkle J, et al. Effect of atazanavir/r on the steady-state pharmacokinetics of elvitegravir. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2007; Chicago.
 
57. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12: 27–35.
 
58. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J AIDS 2010; 55: 323–329.
 
59. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J AIDS 2006; 43: 1–5.
 
60. German P, Liu C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2011; Chicago.
 
61. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25: F7–F12.
 
62. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813–821.
 
63. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012; 56: 1627–1629.
 
64. Eron J, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort 2. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 27– March 2, 2011; Boston.
 
65. Koteff J, Borland J, Song I, et al. An open label, placebo-controlled study to evaluate the effect of dolutegravir (S/GSK1349572) on iohexol and para-aminohippurate clearance in healthy subjects. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2011; Chicago.
 
66. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet Infect Dis 2012; 12: 111–118.
 
67. Eron J, Durant J, Poizot-Martin I, et al. Activity of a next generation integrase inhibitor (INI) S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). Paper presented at: International AIDS Conference; July 18–23, 2010; Vienna.
 
68. Métifiot M, Johnson B, Smith S, et al. MK-0536 inhibits HIV-1 integrases resistant to raltegravir. Antimicrob Agents Chemother 2011; 55: 5127–5133.
 
69. Fenwick C, Bethell R, Cordingley M, et al. BI 224436, a non-catalytic site integrase inhibitor is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2011; Chicago.